WHITE PAPER | OCT 2, 2024

The Annual Clinical Trials Roundup 2024 Edition: Promising Road to Recovery

Trialtrove curated 9,959 Phase I–III clinical trials investigating at least one drug with a disclosed 2023 start, returning growth of 9.4%, a remarkable recovery from the previous year’s decline.

Discover more by downloading the White Paper.

PDF previews of the Annual Clinical Trials Roundup 2024 Edition white paper available for download.
Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

About the author

Headshot of Heidi Chen.

Heidi Chen

Associate Director, Research & Commercial Services, Citeline

Heidi Chen supports client engagement with Citeline content through a deep understanding of customer business needs, seasoned expertise in proprietary platforms, market analysis, and commercial activities. She oversees Citeline's production of customized Platinum Datapacks across hot topic facing industry today.

Heidi draws from her pharmaceutical industry experience as a drug discover scientist and over two decades of therapy-area expertise in CNS, immunology, and ophthalmology. Within this remit, she collaborates across various functional groups within Citeline, and contributes towards projects such as consulting engagements, webinars, and thought leadership white papers.

Related resources

Annual Completed Clinical Trials Report Banner
MAY 22, 2024
White paper
Clinical

Annual Completed Clinical Trials Report

Key insights and results from our annual review of trends in clinical trials completed in 2023, based on Trialtrove data

Exploring Clinical Trial Delays_resource-card-thumbnail
NOV 28, 2023
Article
Clinical

Exploring Clinical Trial Delays

We analyzed data from trials completed during the pandemic to identify trials whose primary completion dates were pushed back by more than six months.

3D model of a RNA strand.
JUL 30, 2024
Report
Commercial

Q2 2024 Gene, Cell, + RNA Therapy Landscape Report

In this report, by Citeline and the American Society of Gene & Cell Therapy (ASGCT), new approvals in Q2 2024 were focused on the RNA landscape.